Retatrutide — Vial
Retatrutide (LY3437943) — synthetic peptide analogue, triple receptor agonist from incretin research (incl. GLP-1R and GIPR). Subject of clinical research (Eli Lilly, Phase 3). Not an approved medicinal product (as of October 2026). Exclusively for scientific research — not for human use.
Contents: 1 × lyophilized peptide powder + 1 × bacteriostatic water (3 ml, Bac Water) for reconstitution. The bacteriostatic water is intended as a solvent for reconstituting the lyophilized peptide and is intended for research purposes only.
Free shipping from 199 €
Shipped from the EU (Czech Republic)
External reports for the tested samples (opens at Janoshik). More under Test reports.
FOR RESEARCH USE ONLY. This product is intended exclusively for laboratory and research purposes. Not for human or animal consumption, not a medicinal product or food.
Retatrutide (synonym: LY3437943) is a synthetic peptide analogue that acts as a simultaneous agonist at three related hormone receptors, including the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). The compound was developed by Eli Lilly and Company and is being investigated in clinical studies in the context of glucose and energy metabolism.
Pharmacological background: triple receptor agonism
In a 2022 paper in Cell Metabolism (DOI: 10.1016/j.cmet.2022.06.010) the molecular pharmacology of LY3437943. The authors describe differential receptor selectivity: retatrutide shows markedly higher potency at GLP-1R than at the third target receptor, indicating a pronounced incretin component. In preclinical models, effects on insulin secretion, hepatic glucose output and energy expenditure were observed.
Clinical development status
Retatrutide is in clinical development by Eli Lilly and Company (including the Phase 2 trial NCT04881760, published by Jastreboff et al., New England Journal of Medicine, 2023; ongoing Phase 3 program). Clinical endpoints are deliberately not presented on this product page – the primary literature is linked below.
Compound characterization
- Development name: LY3437943
- Mode of action: Triple agonist (incl. GLP-1R / GIPR)
- Compound class: Synthetic peptide analog (fatty acid–conjugated)
- Molecular weight: approx. 4,811 g/mol
- Physical state: Lyophilized powder
- Approval status: Not approved (clinical Phase 3, as of October 2026)
- Storage: At −20 °C, protected from light
In the Vial, the substance is supplied as a lyophilized (freeze-dried) powder. Storage recommendation before dissolution: −20 °C, protected from light. Included: 3 ml bacteriostatic water as a solvent for laboratory work.
Solvent, volume, and storage after dissolution are defined in the respective study protocol.
| Name | Retatrutide — Vial |
| Format | Vial – lyophilized powder |
| Analysis reports | 11 × Janoshik Analytical (linked) |
| SKU | SP-RETA-VIAL |
| Storage recommendation | −20 °C, protected from light |
Questions about Retatrutide — Vial
Yes – 11 analysis reports from Janoshik Analytical (HPLC/MS) are linked on this page. They refer to the specific sample tested.
Freeze-drying — the substance is supplied as a powder in the Vial and is dissolved in the lab. 3 ml bacteriostatic water is included.
Shipped within 24–48 hours after receipt of payment from the EU in neutral packaging — to 25 EU countries.
Exclusively for researchers and laboratory users. Not for human or veterinary use, not as a medicinal product, food, or cosmetic.
